Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model-Reference-Cited by-同舟云学术

Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model

Published:2018-09 Issue:9 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pires de Mello Camilly P.¹,Tao Xun²,Kim Tae Hwan²,Vicchiarelli Michael¹,Bulitta Jürgen B.²^ORCID,Kaushik Ajeet³,Brown Ashley N.¹

Affiliation:

1. Institute for Therapeutic Innovation, Department of Medicine, College of Medicine, University of Florida, Orlando, Florida, USA

2. Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA

3. Center for Personalized Nanomedicine, Institute of Neuroimmune Pharmacology, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA

Abstract

Zika virus (ZIKV) infection is associated with serious, long-term neurological manifestations. There are currently no approved therapies for the treatment or prevention of ZIKV infection.

Funder

Florida Department of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00967-18

Reference30 articles.

1. First detection of natural infection of Aedes aegypti with Zika virus in Brazil and throughout South America

2. Probable Non–Vector-borne Transmission of Zika Virus, Colorado, USA

3. Potential Sexual Transmission of Zika Virus